Latest / The Founder's Journey with Fexingo: First-Time Entrepreneurs, Failures, and Lessons Learned / How a Rejected Patent Built a 50M Medical Device Company
Transcript
- Lucas: What happens when the government tells you your invention isn't novel enough? For Dr. Sarah Chen, a rejected patent application turned into a fifty-million-dollar medical device company. Luna: A patent rejection? That's usually a dead end. Most founders I know would pack up and move on. Lucas: Chen almost did. She had developed a wearable sensor for non-invasive glucose monitoring. The patent examiner cited prior art from a university lab — a similar optical technique. She was crushed. Spent six months fighting it, lost, and then had to decide what to do. Luna: Did she pivot immediately? Lucas: Not right away. She actually took a month off, went hiking in Yosemite. And during that trip, she started thinking about the underlying technology differently. The sensor measured molecular concentrations in interstitial fluid. Glucose was one marker, but what about creatinine? That's a key indicator of kidney function. Luna: So she swapped the problem. Instead of diabetes, she went after chronic kidney disease. Lucas: Exactly. And the market was arguably larger. Thirty-seven million Americans have chronic kidney disease, but most don't know it until it's advanced. Early detection is terrible. Chen realized her sensor, with a few tweaks, could give a daily creatinine reading without a blood draw. Luna: That sounds like a whole new product. Did she file a new patent? Lucas: She did. And this time, the patent office approved it. But the real challenge was convincing investors. She pitched to thirty-seven VCs before one said yes. The first check was for five hundred thousand dollars from a healthcare-focused angel. That got them through the first prototype. Luna: Thirty-seven rejections. That's brutal. What was the turning point? Lucas: She realized her pitch was too technical. Investors didn't care about the sensor's wavelength accuracy. They cared about the patient outcome: avoiding dialysis. Once she reframed it as a way to delay kidney failure by six to twelve months, the conversations changed completely. Luna: That's a classic founder lesson — sell the problem, not the technology. Lucas: Right. And she backed it with data. She did a small clinical study with forty patients at a nephrology clinic in San Jose. The results showed her device detected creatinine changes an average of three weeks earlier than standard blood tests. Luna: Three weeks? That's a huge window for intervention. How did the FDA respond? Lucas: That was another rollercoaster. The FDA asked for a larger trial — three hundred patients across five sites. Chen's company, NephroSense, had to raise another three million dollars just to fund it. They got through with a combination of SBIR grants and a second angel round. The trial took eighteen months, but the data was strong enough for a 510 clearance. Luna: I remember reading about that clearance. It was big news in the medtech space. Lucas: Yeah. Once they had FDA approval, the commercial interest picked up fast. They started with a direct to clinic model, but then a large medical device company came calling. Medtronic acquired NephroSense for fifty million dollars last year. Luna: Fifty million. And it all started with a rejection letter from the patent office. That's incredible. Lucas: It really is. And you know, stories like these are exactly why we do the show. If these conversations have moved your work forward in some small way, a couple of dollars a month genuinely keeps these episodes ad-free. Buy me a coffee dot com slash fexingo. Luna: Yeah, it makes a real difference. And it helps us keep bringing you founders like Sarah Chen. Lucas: So back to the acquisition. Medtronic kept the original team intact, and Chen stayed on as VP of product. The device is now being rolled out to dialysis centers nationwide. Luna: That must feel validating after all those early rejections. What's the biggest lesson she shares with other founders? Lucas: She says, 'Your first 'no' is just data. It tells you where the market isn't, not where it can't be.' She also emphasizes that the pivot to kidney disease wasn't random — she followed the science. The sensor was good at measuring small molecules, and creatinine was a perfect fit. Luna: So it wasn't a blind pivot. It was a strategic reframe using the same core IP. Lucas: Exactly. And she warns against falling in love with your first idea. The patent rejection forced her to question her assumptions. That questioning led to a much bigger opportunity. Luna: I also like that she didn't let the thirty-seven VC rejections stop her. Most people would've quit after ten. Lucas: She had a mantra — 'Thirty-seven is just the number of conversations I needed to have before I found the right one.' And that angel investor who wrote the first check? He later said it was the best investment he ever made. Luna: That's a great note to end on. Thanks, Lucas. Lucas: Thanks, Luna. Until next time.